Revance Therapeutics, Inc.

Revance Therapeutics, founded in 2010, is a pharmaceutical company specializing in aesthetic and therapeutic products based on botulinum toxin technology. Headquartered in Nashville, Tennessee, the company became publicly traded through an IPO in 2019. The company's lead product, DaxibotulinumtoxinA (Daxi), is approved for facial aesthetics and therapeutic indications and represents a core component of Revance's commercial strategy. Competing in the aesthetic medicine and specialty pharmaceutical markets, Revance operates as a mid-scale public company focused on injectable solutions. The company serves patients and providers seeking alternatives in the neurotoxin aesthetic and therapeutic markets.